PharmaPoint: Chronic Obstructive Pulmonary Disease – Global Drug Forecast and Market Analysis to 2025

2017-05-30
Price :
Published : May-2017
No. of Pages : 317

PharmaPoint: Chronic Obstructive Pulmonary Disease – Global Drug Forecast and Market Analysis to 2025

Summary

COPD is a progressive lung disease characterized by an abnormal inflammatory response and airflow obstruction that is not fully reversible. Chronic airflow limitation is caused by both small airway diseases, such as obstructive bronchiolitis, as well as parenchymal destruction, including emphysema. Research suggests that the pathogenesis of COPD involves both genetic and environmental factors. The fourth leading cause of death in the world, COPD progresses slowly and symptoms, including shortness of breath, wheezing, chest tightness, cough, and increased mucous production, worsen over time.

Chronic obstructive pulmonary disease (COPD) treatment originated from asthma treatment and exacerbating individuals benefited from the ICS/LABA drug class, leading to even higher sales for GSK’s Advair and AstraZeneca’s Symbicort. Boehringer Ingelheim’s Spiriva (tiotropium) was introduced in the COPD treatment management in 2002, and has since become a global blockbuster as a COPD-targeted therapy with a remarkable impact on patients’ quality of life.

It estimated that the 2015 COPD drug sales to be US$9.9 Billion across the eight major pharmaceutical markets 8MM covered in this report. By the end of the forecast period in 2025, sales will increase to US$14.1 Billion at a Compound Annual Growth Rate (CAGR) of 3.7%, which includes seven pipeline therapies.

COPD is a market with a substantial number of unattained unmet needs, including stakeholders’ recognition of symptoms, treatment that reverses the progression of COPD, and identification of biomarkers. This is not very common for a disease with such an established treatment management and numerous marketed drugs. This is because of the multifactorial causes of the disease combined with a low diagnosis rate across the 8MM. COPD is called the ‘smoker’s disease’ since many of the afflicted individuals are or have been smokers for an extended period of their lives.

Boehringer Ingelheim was the market leader in 2015 with sales of US$3.2 Billion between Striverdi Respimat, Spiriva HandiHaler and Respimat, and Spiolto Respimat across the 8MM. GSK lagged behind with sales of US$2.4 Billion across the LABA, LAMA, LABA/LAMA, and ICS/LABA drug classes, followed by AstraZeneca with sales of US$1.5 Billion between Tudorza Pressair, Duaklir Genuair, and Symbicort. Novartis fell behind with sales of US$443.3 million without a blockbuster therapy in the COPD market.

The report “PharmaPoint: Chronic Obstructive Pulmonary Disease – Global Drug Forecast and Market Analysis to 2025”, Overview of COPD, including epidemiology (mMRC and CAT patient population), etiology, pathophysiology, symptoms, diagnosis, and current management strategies.

In depth, this report provides the following analysis –
– Topline COPD market revenue from 2015-2025. ACOT and major pipeline product sales in this forecast period are included.
– Presents the key metrics for chronic obstructive pulmonary disease (COPD) in the eight major pharmaceutical markets (8MM) – the US, 5EU (France, Germany, Italy, Spain, and the UK), Japan, and Australia-during the forecast period from 2015-2025.
– Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting COPD therapeutics sales in the 8MM.
– Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
– Analysis of the current and future market competition in the global COPD therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Companies mentioned in this report: AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Novartis, Sunovion.

Scope

– Overview of COPD, including epidemiology (mMRC and CAT patient population), etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
– Topline COPD market revenue from 2015-2025. ACOT and major pipeline product sales in this forecast period are included.
– Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting COPD therapeutics sales in the 8MM.
– Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
– Analysis of the current and future market competition in the global COPD therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to –
– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
– Develop business strategies by understanding the trends shaping and driving the global COPD therapeutics market.
– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the COPD therapeutics market in the future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
– Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
Publisher : GlobalData
More Reports
Title Price Buy Now

Pharmaceutical Gelatin Market by Source (Porcine, Bovine Skin, Bovine Bone, Fish, Poultry), Application (Hard Capsule, Soft Capsule, Tablet, Absorbable Hemostat), Function (Stabilizing, Thickening, Gelling), Region – Global Forecast to 2025

“The global pharmaceutical gelatin market is projected to grow at a CAGR of 5.3%.” The global pharmaceutical gelatin market is projected to reach USD 1.2 billion by 2025 from USD 1.0 billion in 2020, at a CAGR of 5.3% during the forecast period. Growth in this market is driven by the advantages of pharmaceutical gelatin such as utility and versatility in medical and biomedical applications, unique functional properties, natural source of origin, and the increasing demand for pharmaceutical applications such as hard capsules and soft gel capsules. However, factors such as cultural restrictions in consumption of porcine or bovine-derived gelatin, and rising prices of raw material are expected to restrain the growth of this market to a certain extent during the forecast period. “T......
$5650

Active Pharmaceutical Ingredient (API) Market by type (Innovative, generic), manufacturer (captive, merchant), synthesis (synthetic, biotech), by product (vaccines, Hormones), drug (OTC, Rx), application (Diabetes, oncology, CVD) – Global Forecast to 2025

““Increasing incidence of chronic diseases and technological advancements in API manufacturing,is expected to drive the overall growth of the global APIs market” The global active pharmaceutical ingredients market is projected to reach USD 248.3 billion by 2025 from USD 187.3 billion in 2020, at a CAGR of 5.8% during the forecast period. Growth in the active pharmaceutical ingredients market is primarily driven by factors such as growing use of immunoglobulins in various therapeutic areas, increase in plasma collection (and the number of plasma collection centers), rising geriatric population, and the growing prevalence of respiratory diseases and alpha-1-antitrypsin deficiency (AATD). However, the high cost of plasma products, limited reimbursements, and the emergence of recombin......
$4950

Partnerships, Licensing, Investments, Mergers and Acquisitions Deals and Trends in Pharmaceuticals – August 2020

Partnerships, Licensing, Investments, Mergers and Acquisitions Deals and Trends in Pharmaceuticals - August 2020 Summary GlobalData's "Partnerships, Licensing, Investments, Mergers and Acquisitions Deals and Trends in Pharmaceuticals - August 2020" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in August 2020. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies.......
$1000

External Remote Patient Monitoring Devices – Medical Devices Pipeline Assessment, 2020

External Remote Patient Monitoring Devices - Medical Devices Pipeline Assessment, 2020 Summary GlobalData's Medical Devices sector report, "External Remote Patient Monitoring Devices - Medical Devices Pipeline Assessment, 2020 " provides comprehensive information about the External Remote Patient Monitoring Devices pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. External remote patient monitoring devices retrieves the data from the external measurement device (like glucose meters, blood pressure monitors. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type. Scope - Extensive coverage......
$4000

Vital Sign Monitors – Medical Devices Pipeline Assessment, 2020

Vital Sign Monitors - Medical Devices Pipeline Assessment, 2020 Summary GlobalData's Medical Devices sector report, "Vital Sign Monitors - Medical Devices Pipeline Assessment, 2020 " provides comprehensive information about the Vital Sign Monitors pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. Vital sign monitors are used to measure and record the basic vital signs such as pulse rate, temperature and respiratory rate of an individual. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type. Scope - Extensive coverage of the Vital Sign Monitors under development - The report reviews det......
$4000

Coronavirus Disease 2019 (COVID-19) Analyst Consensus Drug Sales Forecast, Q2 2020

Coronavirus Disease 2019 (COVID-19) Analyst Consensus Drug Sales Forecast, Q2 2020 Summary This report contains a summary of the analyst consensus forecasts available in the GlobalData Pharma Intelligence Center Drug Sales and Analyst Consensus Database for the Indication COVID-19. Since the last edition of this report the number of COVID-19 therapies and vaccines with forecasts have increased dramatically. This report features the 14 most prominent drugs indicated for COVID-19 which have analyst consensus forecasts available. Scope This report is required reading for - - Investors that want to understand how COVID-19 has impacted Drug Revenues in the biopharmaceutical industry as well as identifying companies to invest in - Companies that are interested in entering the COVID-19 disea......
$495

Crohn’s Disease – Global Drug Forecast and Market Analysis to 2029

Crohn's Disease - Global Drug Forecast and Market Analysis to 2029 Summary Crohn's disease (CD) is a form of inflammatory bowel disease (IBD), which is composed of two chronic autoimmune diseases that cause intestinal inflammation: Crohn's disease (CD) and ulcerative colitis (UC). In CD, chronic inflammation may affect any part of the gastrointestinal (GI) tract from the mouth to the anal area; however, CD occurs most commonly in the lower part of the small intestine (ileum) and in the large intestine. The pathophysiology of CD is complex, as the disease is characterized by recurring flares that evolve along with periods of inactivity and remission. The CD market has historically been reliant on anti-tumor necrosis factor (anti-TNF) therapies that have been available for over a decade bu......
$10995

Coronavirus Disease (COVID-19) Implications on Health Insurance – August 2020

Coronavirus Disease (COVID-19) Implications on Health Insurance - August 2020 Summary The highly contagious coronavirus (SARS-CoV-2), dubbed COVID-19 (formerly 2019-nCoV), which emerged at the close of 2019, has led to a medical emergency across the world, with the World Health Organization (WHO) officially declaring the novel coronavirus a pandemic on March 11, 2020. The virus is also having a growing impact on the global economy including the health insurance industry. This report reflects how government bodies and healthcare authorities are reacting to protect policyholder interest and minimize the impact on the health insurance industry during the COVID-19 crisis. Key Highlights - Changes to certain telemedicine regulations are likely to be made permanent: The announcement of an E......
$495

Topical Drug Delivery Market by Type (Semisolids (Creams, Ointments, Gels, Lotions, Liquids, Solids, Transdermal Products), Route (Dermal, Rectal, Vaginal), Patient Care Setting (Homecare, Hospital, Burn Center) COVID-19 Impact – Global Forecast to 2025

The topical drug delivery market is expected to grow at a CAGR of 6.4% in the forecast period. The topical drug delivery market is projected to reach USD 129.8 billion by 2025 from USD 95.2 billion in 2020, at a CAGR of 6.4% during the forecast period. The growth of this market is majorly driven by the high prevalence of skin and soft tissue infections, the increasing prevalence of eye diseases, and burns.However, the presence of alternative drug delivery modes such as oral and injectable routes is expected to restrain the growth of this market during the forecast period. Based on product, the semi-solid formulations segment holds the largest market share during the forecast period. Based on product, the topical drug delivery market is segmented into semi-solid formulations, liqui......
$4950

Cleanroom Technologies Market by Product (HVAC, HEPA Filters, Apparel, Vacuum Systems, Gloves, Disinfectants), Construction (Drywall, Hardwall, Softwall), End User (Pharmaceutical, Biotechnology, Hospitals) – COVID-19 Impact – Global Forecast to 2025

The cleanroom technologies market is expected to grow at a CAGR of 7.2 % in the forecast period. The cleanroom technologies market is projected to reach USD 7.3 billion by 2025 from USD 5.1 billion in 2020, at a CAGR of 7.2% during the forecast period. The growth of this market is majorly driven by the stringent regulatory framework, growth of the biologics sector, rising demand for sterilized pharmaceutical formulations, increasing demand for medical devices, and technological advancements in cleanroom technology. Also, the increasing demand in developing economies and the growing focus on energy-efficient cleanrooms are expected to offer significant opportunities for market growth in the coming years. However, the high operational cost associated with the cleanrooms is expected to res......
$4950
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy